Industrial Liaison News
Industrial Liaison works with NYU entrepreneurs and inventors to develop new technologies and launch successful startups. Read the latest news about our ventures.
Johnson & Johnson paid $140 million to buy oncolytic immunotherapy startup BeneVir Biopharm. BeneVir Biopharm was founded on intellectual property and research by Ian J. Mohr, PhD, a professor in NYU Langone’s Department of Microbiology.
Soligenix, a clinical stage biopharmaceutical company, has acquired the rights for SGX301 (synthetic hypericin), a phase 3 asset being developed for cutaneous T-cell lymphoma, from Hy Biopharma. Hy Biopharma was founded on intellectual property and research from Daniel Meruelo, PhD, a professor in NYU Langone’s Department of Pathology, and Gad Lavie, PhD.
BrainScope Company, Inc., a medical neurotechnology company that created the first U.S. Food and Drug Administration (FDA)–cleared handheld medical device used to assess the full spectrum of traumatic brain injury, announced it has completed a $16 million equity financing round. BrainScope Company’s technology is based on intellectual property and research based on the work of Leslie S. Prichep, PhD, former faculty in NYU Langone’s Department of Psychiatry.
TitletownTech announced it has invested $8 million in Oculogica, an innovative digital health company. Oculogica has established the new standard of care for concussion diagnosis through the development of the EyeBOX, the first FDA-approved neuro-diagnostic device that uses proprietary and innovative technology to track eye movement to determine if a person has a concussion. Oculogica was co-founded by Uzma Samadani, MD, PhD, former faculty in NYU Langone’s Departments of Neurosurgery, Psychiatry, and Neuroscience and Physiology, and Robert Ritlop and Steve Ogilivie, graduates of NYU Stern School of Business.
Guardant Health announced that it has priced an underwritten public offering of 11.5 million shares of its common stock at $84 per share. Guardant Health is based on technology developed by inventors at NYU.
Spin Memory, Inc., the leading MRAM developer, announced its $52 million Series B funding round. Spin Memory is based on spin transfer magnetoresistive random access memory technology, OST-MRAM, originally developed by Andrew D. Kent, PhD, a professor in NYU’s Department of Physics.
Repare Therapeutics, which develops novel medicines that target genetically defined weaknesses of cancers, raised a $68 million Series A financing. Repare Therapeutics was co-founded by Agnel Sfier, PhD, an associate professor in NYU Langone’s Department of Cell Biology.